```html

Isoniazid‑Induced Hepatitis – A Comprehensive Patient Guide

Overview

Isoniazid‑induced hepatitis is an inflammation of the liver that occurs as an adverse reaction to the antibiotic isoniazid (INH). Isoniazid is a first‑line medication used worldwide for the prevention and treatment of tuberculosis (TB). While most people tolerate the drug well, up to 2–5 % of adults develop clinically significant hepatitis, and the risk rises to 10–20 % in certain high‑risk groups.

The condition typically appears within the first 2–3 months of therapy, but it can occur at any time during a 6‑ to 9‑month treatment course. It is more common in:

• Older adults (especially >35 years)
• Women
• People with pre‑existing liver disease or chronic viral hepatitis (HBV, HCV)
• Alcohol users (≥2–3 drinks per day)
• Patients who are fast acetylators (genetic variation that speeds drug metabolism)

According to the World Health Organization (WHO), >10 million people receive isoniazid each year; even a low incidence translates to thousands of hepatitis cases globally.

Symptoms

Symptoms of isoniazid‑induced hepatitis overlap with other forms of liver injury. Not everyone experiences noticeable signs, which is why routine laboratory monitoring is essential.

• Fatigue or weakness – often the earliest clue.
• Right‑upper‑quadrant abdominal pain – may feel like a dull ache or pressure.
• Jaundice – yellowing of the skin and eyes, indicating elevated bilirubin.
• Dark urine – urine may turn tea‑colored due to bilirubin excretion.
• Clay‑colored stools – a sign of impaired bile flow.
• Nausea, vomiting, or loss of appetite – common but nonspecific.
• Pruritus (itching) – caused by bile salts depositing in the skin.
• Fever or chills – less common, may indicate severe inflammation.
• Elevated liver enzymes on routine blood tests (often asymptomatic).

If you notice any of these symptoms, especially jaundice or severe abdominal pain, contact your healthcare provider promptly.

Causes and Risk Factors

How Isoniazid Causes Liver Injury

Isoniazid is metabolized primarily in the liver by the enzyme N‑acetyltransferase 2 (NAT2). During metabolism, reactive intermediates (e.g., hydrazine) are produced. In susceptible individuals, these metabolites bind to liver proteins, triggering oxidative stress and an immune‑mediated inflammatory response that damages hepatocytes.

Key Risk Factors

• Age > 35 years – hepatic regenerative capacity declines with age.
• Female sex – hormonal and metabolic differences may increase susceptibility.
• Pre‑existing liver disease – chronic hepatitis B/C, fatty liver disease, or cirrhosis.
• Genetic polymorphism – “slow acetylators” have higher drug exposure; “fast acetylators” generate more toxic metabolites.
• Alcohol consumption – synergistic hepatotoxic effect.
• Concurrent hepatotoxic drugs – e.g., rifampin, pyrazinamide, methotrexate, certain antiretrovirals.
• High daily dose – >300 mg/day increases risk; pediatric dosing follows mg/kg guidelines to mitigate this.

Diagnosis

Diagnosing isoniazid‑induced hepatitis is a process of exclusion—ruling out other causes of liver injury while correlating clinical timing with drug exposure.

Clinical Evaluation

• Detailed medication history (including start date, dose, and adherence).
• Review of alcohol intake, recent illnesses, and other drugs.
• Physical exam focusing on liver size, tenderness, and signs of jaundice.

Laboratory Tests

• Liver function panel – ALT and AST are usually >3× upper limit of normal (ULN); ALT is the most sensitive marker.
• Alkaline phosphatase (ALP) and γ‑glutamyl transpeptidase (GGT) – may be mildly elevated.
• Total bilirubin – rises when cholestasis occurs; >2 mg/dL is concerning.
• Serum albumin and coagulation profile (PT/INR) – assess synthetic function; an INR > 1.5 suggests severe impairment.
• Viral hepatitis serologies (HBsAg, anti‑HBc, anti‑HCV) to exclude infectious causes.
• Autoimmune markers (ANA, SMA) if autoimmune hepatitis is suspected.

Imaging

• Abdominal ultrasound – rules out biliary obstruction, gallstones, or focal lesions.
• CT or MRI is rarely needed unless there is suspicion of alternative pathology.

Diagnostic Criteria (CDC/WHO)

Diagnosis is generally made when any of the following are present while on isoniazid therapy:

1. ALT or AST ≥ 3 × ULN plus symptoms (e.g., nausea, abdominal pain, jaundice); or
2. ALT or AST ≥ 5 × ULN without symptoms.

Persistent elevation after drug cessation for >7 days warrants further hepatology referral.

Treatment Options

Immediate Management

• Discontinue isoniazid – the cornerstone of therapy. Stop the drug as soon as liver injury is suspected.
• Supportive care – adequate hydration, anti‑emetics for nausea, and analgesics (acetaminophen safe at ≤ 2 g/day; avoid NSAIDs if severe liver injury).
• Monitoring – repeat liver enzymes every 48–72 hours until they trend down.

Alternative TB Regimens

If TB treatment must continue, replace isoniazid with another effective agent, guided by susceptibility testing:

• Rifampin (4‑month regimen) – WHO‑recommended for latent TB when INH cannot be used.
• Levofloxacin or moxifloxacin – fluoroquinolones used in multidrug‑resistant contexts.
• Ethambutol, pyrazinamide – only if disease is active and susceptibility confirmed.

Corticosteroids

Evidence for steroids in drug‑induced hepatitis is limited. They may be considered in severe, immune‑mediated cases under hepatology supervision, but routine use is **not** recommended.

Liver‑Specific Treatments

• N‑acetylcysteine (NAC) – antioxidant therapy shown to improve outcomes in acute liver failure; used on a case‑by‑case basis.
• Liver transplant – reserved for fulminant hepatic failure (acute liver failure with encephalopathy, INR > 1.5). Survival rates exceed 70 % with timely transplantation.

Lifestyle & Adjunct Measures

• Complete abstinence from alcohol.
• Balanced diet rich in fruits, vegetables, and lean protein to support hepatic regeneration.
• Avoid over‑the‑counter hepatotoxic supplements (e.g., kava, high‑dose vitamin A).

Living with Isoniazid‑Induced Hepatitis

Monitoring Schedule

• Baseline labs before starting INH.
• Repeat LFTs at 2 weeks, 1 month, and then monthly for the first 3 months (CDC recommendation).
• If LFTs are normal, continue routine checks every 2–3 months.

Self‑Care Tips

• Keep a medication diary – note any new symptoms.
• Stay hydrated – aim for 2 L of water per day unless fluid‑restricted.
• Limit fatty and fried foods which can stress the liver.
• Engage in moderate exercise (30 min most days) to maintain a healthy weight.
• Discuss any herbal or dietary supplements with your clinician before use.

Emotional Support

Being diagnosed with drug‑induced hepatitis can be stressful, especially when treatment for TB is interrupted. Consider:

• Joining a TB support group (online or community‑based).
• Talking with a mental‑health professional if anxiety or depression arises.
• Keeping open communication with your healthcare team about concerns.

Prevention

• Baseline screening – check LFTs, hepatitis B/C status, and alcohol use before initiating isoniazid.
• Dose adjustment – use weight‑based dosing (5 mg/kg, max 300 mg/day) and avoid unnecessarily high doses.
• Genetic testing (optional) – NAT2 genotyping can identify fast acetylators, though routine testing is not yet standard.
• Avoid concurrent hepatotoxins – coordinate all medications with your prescriber.
• Patient education – ensure patients know the warning signs and the importance of follow‑up labs.

Complications

If not recognized early, isoniazid‑induced hepatitis can progress to:

• Acute liver failure – encephalopathy, coagulopathy, and potential need for transplant.
• Chronic liver disease – persistent inflammation may lead to fibrosis or cirrhosis.
• Interrupted TB therapy – leading to disease relapse or development of drug‑resistant TB.
• Systemic effects – such as renal impairment from hepatorenal syndrome.

When to Seek Emergency Care

Key Take‑Away Points

• Isoniazid is an essential TB drug, but it can cause hepatitis, especially in older adults, women, and those with existing liver disease.
• Routine liver‑function testing during the first 3 months of therapy is vital for early detection.
• Prompt discontinuation of isoniazid and appropriate alternative TB treatment usually lead to full recovery.
• Patients should be educated about symptoms and maintain regular follow‑up with their healthcare team.

For personalized advice, always discuss your individual risk factors and treatment plan with a qualified clinician.

```